MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

This new $110 million, 140,000-square footfacility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a marketexpected to grow to $10 billion by 2026.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Tuesday, October 12, 2021
Information
Tags: 
Entrepreneurship, Merck Group, Electronics, Health, Food and Drug Administration, Solution, Food, List of life sciences, Multimedia, Merck, Federal Executive Boards, LinkedIn, Growth, Körber Process Solutions, Investment, Board of directors, Adoption, Thailand Center of Excellence for Life Sciences, CDMO, CEO, Degenerative disease, Intelligence, Science, Patient, Merck Millipore, Merck Serono, Fine chemical, Pharmaceutical industry, Vaccine, Mail
Geotags: 
California, Massachusetts, CANADA, UNITED STATES, CARLSBAD, GERMANY, DARMSTADT
Organisation: 
MILLIPORESIGMA
Summary
Key Points: 
  • This new $110 million, 140,000-square footfacility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a marketexpected to grow to $10 billion by 2026.
  • "As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market."
  • The new facility leverages cutting-edge suspension technology to enable scalable and cost-effective manufacturing.
  • "We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients," Heinzel added.


MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

  • Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors
  • Investment serves customers in addressing larger patient populations with new curative treatments
  • Enables suspension production of viral vectors up to 1,000-liter scale
  • Project adds to company's ambition to accelerate growth through investments in "Big 3" businesses, which includes plans to expand Process Solutions' contract manufacturing and development organization (CDMO) services for traditional and novel modalities

BURLINGTON, Mass., Oct. 12, 2021 /PRNewswire/ -- MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the opening of its second Carlsbad, California-based facility, significantly expanding its CDMO footprint. This new $110 million, 140,000-square foot facility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a market expected to grow to $10 billion by 2026.

"Today, most gene therapies target rare diseases, but there is an urgent need to efficiently manufacture these treatments to reach larger patient populations," said Matthias Heinzel, Member of the Executive Board and CEO, Life Science, Merck KGaA, Darmstadt, Germany. "As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market."

This is the company's second Carlsbad, California-based facility to serve cell and gene therapy customers driven by the industry's rapid adoption of viral vector-based therapies. Between the two facilities, there are 30 cleanroom suites to support all aspects of manufacturing from small- to large-scale clinical and commercial production. The new facility leverages cutting-edge suspension technology to enable scalable and cost-effective manufacturing.

"We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients," Heinzel added.

The expansion of the Carlsbad facility adds to the company's ambition to accelerate growth through investments in the "Big 3", including the Process Solutions business unit within the Life Science business sector as a key driver. 

The Life Science business of Merck KGaA, Darmstadt, Germany has proven its commercial execution and global regulatory success as one of the first CDMOs to be granted U.S. Food and Drug Administration and European Medicines Agency approval for viral vector manufacturing. With nearly 30 years of experience in cell and gene therapy, the Life Science business of Merck KGaA, Darmstadt, Germany offers unique CDMO services streamlined as a single, highly experienced provider.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 58,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/milliporesigma-announces-completion-of-new-viral-vector-contract-development-manufacturing-facility-for-gene-therapy-301397375.html

SOURCE MilliporeSigma

Copyright: 
2021 PR Newswire. All Rights Reserved.